Closing the door on flaviviruses: entry as a target for antiviral drug design.
With the emergence and rapid spread of West Nile virus in the United States since 1999, and the 50-100 million infections per year caused by dengue virus globally, the threat of flaviviruses as re-emerging human pathogens has become a reality. To support the efforts that are currently being pursued to develop effective vaccines against these viruses, researchers are also actively pursuing the development of small molecule compounds that target various aspects of the virus life cycle. Recent advances in the structural characterization of the flaviviruses have provided a strong foundation towards these efforts. These studies have provided the pseudo-atomic structures of virions from several members of the genus as well as atomic resolution structures of several viral proteins. Most importantly, these studies have highlighted specific structural rearrangements that occur within the virion that are necessary for the virus to complete its life cycle. These rearrangements occur when the virus must transition from immature, to mature, to fusion-active states and rely heavily on the conformational flexibility of the envelope (E) protein that forms the outer glycoprotein shell of the virus. Analysis of these conformational changes can suggest promising targets for structure-based antiviral design. For instance, by targeting the flexibility of the E protein, it might be possible to inhibit required rearrangements of this protein and trap the virus in a specific state. This would interfere with a productive flaviviral infection. This review presents a structural perspective of the flavivirus life cycle and focuses on the role of the E protein as an opportune target for structure-based antiviral drug design.
Perera
Rushika
R
Markey Center for Structural Biology and Department of Biological Sciences, Purdue University, West Lafayette, IN 47907, USA.
Khaliq
Mansoora
M
Kuhn
Richard J
RJ
D000998:Antiviral Agents / Q000737:chemistry / Q000494:pharmacology*; D015195:Drug Design; D005416:Flavivirus / Q000145:classification / Q000187:drug effects* / Q000472:pathogenicity* / Q000502:physiology; D006801:Humans; D008958:Models, Molecular; D011487:Protein Conformation; D014759:Viral Envelope Proteins / Q000737:chemistry / Q000378:metabolism; D053586:Virus Internalization / Q000187:drug effects*
D000998:Antiviral Agents; D014759:Viral Envelope Proteins